Description
TB-500 supplied as a research reagent for in-vitro laboratory use. Every lot is assayed by reverse-phase HPLC to ≥98% purity, with identity confirmed by mass spectrometry and residual water content checked by Karl Fischer titration. Purity is verified across multiple independent laboratories, and material is sourced across multiple manufacturers so the highest-purity batch can be selected for release.
Specification
- CAS number: 77591-33-4
- Physical form: Lyophilised powder
- Purity: ≥98% by RP-HPLC
- Storage: 2°C – 8°C, protect from light
Research findings
- Full-length thymosin β4 is characterised as the principal intracellular G-actin sequestering peptide, binding actin monomers at approximately 1:1 and inhibiting polymerisation to F-actin [1, 3]
- Identified as an actin-sequestering peptide, indistinguishable from the previously described Fx peptide [1]
- Found to sequester the majority of G-actin in resting human neutrophils, at cytoplasmic concentrations around 150 µM [2]
- Shown alongside thymosin β10 to bind skeletal muscle actin and inhibit polymerisation, with Kd values of roughly 0.7–1 µM [3]
- All of the above concerns the 43-residue parent protein, not the 7-residue fragment supplied; we are not aware of published work establishing equivalent actin-binding behaviour for the fragment
Regulatory status
RESEARCH USE ONLY — NOT FOR HUMAN CONSUMPTION. Supplied strictly for in-vitro laboratory research by qualified professionals. Not a medicine, supplement, cosmetic or food. Must not be administered to humans or animals.
Vial and carton labels show 99% purity — the specification we aim for on every batch. Our guaranteed minimum is ≥98% by RP-HPLC, and the measured result for each batch appears on its certificate of analysis.
Reviews
There are no reviews yet.